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Background: Nonalcoholic fatty liver disease (NAFLD) is one of the commonest liver disorders. Obesity, insulin
resistance, lipid peroxidation and oxidative stress have been identified amongst the possible hits leading to the
onset and progression of this disease. Nutritional evaluation of NAFLD patients showed a lower-than-recommended
intake of vitamin E. Vitamin E is a family of 8 isoforms, 4 tocopherols and 4 tocotrienols. Alpha-tocopherol has been
widely investigated in liver diseases, whereas no previous clinical trial has investigated tocotrienols for NAFLD. Aim
of the study was to determine the effects of mixed tocotrienols, in normalising the hepatic echogenic response in
hypercholesterolaemic patients with ultrasound-proven NAFLD.
Methods: Eighty-seven untreated hypercholesterolaemic adults with ultrasound-proven NAFLD were enrolled and
randomised into control group (n = 44) and tocotrienols group (n = 43). The treatment, either mixed tocotrienols
200 mg twice daily or placebo, had a 1-year duration.
Normalisation of hepatic echogenic response, being the trial primary aim, was used in sample size calculations.
The data were assessed according to intention to treat principle as primary outcome. Per protocol analysis was also
carried out as secondary outcome measurement.
Results: Thirty and 34 participants concluded the study in the tocotrienols and placebo group respectively.
Alpha-tocopherol levels were within the normal range for all subjects. As primary outcome, the normalisation of
hepatic echogenic response was significantly higher for the tocotrienols treated group compared to the placebo
group in the intention to treat analysis (P = 0.039; 95% CI = 0.896-6.488). As secondary objective, the per protocol
assessment also showed significant rate of remission (P = 0.014; 95% CI = 1.117-9.456). Worsening of NAFLD grade
was recorded in two patients in the placebo group, but none in the group treated with tocotrienols. No adverse
events were reported for both groups.
Conclusion: This is the first clinical trial that showed the hepatoprotective effects of mixed palm tocotrienols in
hypercholesterolemic adults with NAFLD.
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In recent years research on non-alcoholic fatty liver
disease (NAFLD) has been intensified indicating an
increased interest in this common hepatic disorder.
Lipid peroxidation and oxidative stress have been recog-
nised as playing a pivotal role in the pathogenesis and
progression of NAFLD [1,2]. Nutritional assessment of
NAFLD patients showed a lower-than-recommended
intake of vitamin E [3], possibly leading to low plasma
concentration of antioxidants. Recent clinical studies
suggested vitamin E to be one of the most promising
agent for amelioration of non-alcoholic steatohepatitis
(NASH) in adults [4] and up to a certain extent in
youngsters [5]. The most common homologue of the
vitamin E family investigated is alpha-tocopherol. Other
homologues of vitamin E, namely tocotrienols, also exist
in isomers designated as alpha, beta, gamma and delta,
and they differentiate from analogous isomers of toco-
pherol by the presence of an unsaturated phytyl chain
(‘tail’) as opposed to a saturated one in tocopherols.
Tocotrienols are preferentially distributed to the liver
[6,7] and alpha-tocotrienol has been reported to be 40-
60 times more potent than alpha-tocopherol against
lipid peroxidation in rat liver microsomes [8].
Prevalence of NAFLD in Asia has been showed in a
recent review to be similar to Western countries [9],
with local data in hypercholesterolaemic adults indicat-
ing a NAFLD prevalence of about 60% [10]. Concerns
about the high prevalence of NAFLD and the not fully
understood reasons for its progression to more severe
form of liver diseases, have led to the initiation of this
interventional, double-blind placebo-controlled study. The
aim of the investigation was to evaluate the activity of
tocotrienols in normalising hepatic echogenic response in




Volunteers of both genders aged 35 years and above
with mild untreated hypercholesterolaemia and ultra-
sound-proven NAFLD, selected from a population-based
study on the prevalence of NAFLD [10] were assessed
for eligibility. Mild hypercholesterolemia, assessed during
screening, was defined as ranging between 5.2 and
6.2 mmol/L (200-240 mg/dL) for total cholesterol and
between 2.6 mmol/L and 4.2 mmol/L (100-161 mg/dL)
for LDL-cholesterol. Alcohol intake, assessed through
interview, had to be less than 20 g/day. Alanine
transaminase (ALT), aspartate transaminase (AST)
and gamma-glutamyl transpeptidase (GGT) had to be
below 3 times the respective upper limit value of
53 IU/L, 40 IU/L and 49 IU/L for male or 32 IU/L
for female.Volunteers were excluded if they were presented in the
3 months prior to enrolment with anti-hyperlipidemic
treatment and/or vitamin E intake and history of abuse
or excessive intake of alcohol, previous cardiovascular
events or hepatitis. No specific dietary guidance was
given to the participants, however they were advised
about the overall health benefits of increased physical
activity and fat-reduced diet.
Participants were recruited at Universiti Sains Malaysia
facilities in Kepala Batas Hospital (Penang, Malaysia),
between February 2008 and June 2009. Out of 102
hypercholesterolaemic adults with ultrasound-proven
NAFLD assessed for eligibility, 87 fulfilled the inclusion
criteria and were enrolled by the investigators EM and
YG, who also dispensed the treatments.
The present interventional study (http://www.clinical-
trials.gov/show/NCT00753532), designed as a parallel
double-blind placebo-controlled study, was approved by
the Research Ethics Committee for Human Studies of
Universiti Sains Malaysia. Participants were enrolled upon
signing informed consent.
Randomisation and treatment
The treatment assigned to participants for 1 year was
either mixed tocotrienols 200 mg twice daily or placebo.
The content in each capsule of the mixed tocotrienols
preparation was 61.5 mg, 112.8 mg and 25.7 mg for
alpha-, gamma- and delta-tocotrienol, respectively and
61.1 mg of alpha-tocopherol. Both placebo and tocotrie-
nols, were soft gel capsules and were similar in terms of
colour, size, shape and surface texture. Participants were
randomised using a computer generated random alloca-
tion sequence. A permuted block design was employed.
Each block of specified size contained allocation ratio of
1:1 (placebo:tocotrienols). The random allocation se-
quence would select the next block and determine the
next allocations. Sequence was not made known to
researchers who enrolled participants. For the purpose
of assigning participants to interventions, a subject num-
ber was used. The researcher (WJW) who generated the
random allocation sequence and assigned participants
was blinded to subjects’ clinical data and was independ-
ent from the persons who enrolled participants.
The mixed tocotrienols preparation (Tocovid Suprabio®)
and the placebo capsules were purchased from Hovid
(Ipoh, Malaysia). Researchers and volunteers were blinded
to the assigned treatment.
Clinical and metabolical evaluation
Quarterly, after an overnight fast, a 12 ml blood sample
from each volunteer was withdrawn and analysed by an
accredited laboratory for levels of serum total cholesterol
(TC), LDL-cholesterol, HDL-cholesterol, triglycerides
(TG), apolipoprotein B (ApoB), lipoprotein A (LP(A)),
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glucose, serum creatinine, alkaline phosphatase (ALP),
ALT, AST and GGT. Body mass index (BMI) and blood
pressure were measured. Moreover, participants were
asked to recall their lifestyle habits (such as food intake
and physical activity). Compliance to the study treat-
ment was assessed through patient recall, capsule count
and plasma levels of tocotrienols. Plasma tocotrienol
concentrations were measured using a validated high-
performance liquid chromatographic (HPLC) method [11]
after completion of the study, until then the samples were
kept at -80°C. Quantitative HPLC analysis of plasma
tocotrienol concentrations were performed to determine
adherence to the treatment. Investigation of the associ-
ation of plasma level of tocotrienols with response was
not the aim of the present study.
High sensitivity B-mode ultrasonography (USG) exam-
ination was performed at baseline and after 1 year by the
same experienced radiologists (MAA and ILS, in pres-
ence of a third radiologist, MRAB) using the same
instrument, a Pentax-Hitachi EUB6500 (Tokyo, Japan)
fitted with a EUP-C516 (3.5-5.0 MHz) probe using the
standard adult abdominal settings, throughout the study.
The radiologists were unaware of the clinical, metabolic
and USG baseline conditions of the subjects. The USG
evaluation consisted of a visual scoring system evaluat-
ing three aspects of interest: hepatorenal echodiscre-
pancy, posterior echo-penetration and portal vein wall
clarity. Each of the three hepatic aspects considered was
given a score of zero, if normal, 1 or 2 according to the
echogenicity of the response [12]. Hepatic aspects and
relative scoring system are detailed in Table 1. The
values were then summed up and a total score of 3 andTable 1 Criteria of the hepatic aspects considered and
relative scoring system for ultrasonographic diagnosis of
nonalcoholic fatty liver disease
Criteria Score
Liver/kidney parenchyma
a) Homogeneous echotexture and absence of
significant contrast with kidney parenchyma
0
b) Slight increase in liver/kidney echodiscrepancy 1
c) Extreme echodiscrepancy between liver and kidney 2
Portal vein walls clarity
a) Clear definition of portal vein walls and structures 0
b) Decreased definition of portal vein walls and structures 1
c) Blurred visualisation of portal vein walls 2
Posterior echo-penetration
a) Clear definition of hepatic structures from diaphragm 0
b) Decreased definition of liver and diaphragm structures 1
c) Blurred diaphragm with loss of definition 2
(Adapted from [12]).above was diagnosed as fatty liver. Steatosis was graded as
mild (score 3), moderate (score 4) or severe (score 5-6).
Only diffuse hyperechogenicity of the liver parenchyma
was acceptable, whereas focal or patchy responses were
excluded.
Statistical analysis
Prospective estimation of the sample size for a binary
outcome trial with 5% significance level (alpha) and 80%
power was calculated according to Pocock [13]. There-
fore, the minimum number of patients required per arm
was calculated to be 20. The binary outcomes considered
were normalisation of echogenic response versus no-
improvement or worsening.
Difference in proportion of participants that have been
found with normal echogenic response at conclusion of
the study between each group of treatment were assessed
using Helmert-Pearson’s Chi-square test. The effects of
independent variables, such as blood parameters and
anthropometric data, were evaluated using ANOVA for
split-plot design adjusted for unweighted-means [14].
Homogeneity of baseline characteristics was calculated
using Wilcoxon Rank Test. Statistical calculations were
performed using Numbers’09 (Apple, Cupertino, CA,
USA) and QuickCalcs or InStat 3.1a for Macintosh
(GraphPad Software, San Diego California USA).
The study primary end-point was a normalisation of
hepatic echogenic response, defined as homogeneous
hepatic echotexture with absence of significant contrast
with kidney parenchyma, clear definition of portal vein
walls and clear definition of hepatic structures from
diaphragm (Table 1). The data were assessed according
to intention to treat and per protocol analyses. Drop-out




The study participants self-reported mostly sedentary
lifestyles, with none of them engaged in regular physical
exercise of minimum 30 minutes 3-time weekly. Out of
87 enrolled patients 64 completed the investigation. In
the tocotrienols group 8 subjects withdrew consent, 3
were excluded for protocol violation and 2 did not come
for the final USG follow-up. Similarly, in the placebo
group 6 subjects withdrew consent, 2 were excluded for
protocol violation and 2 did not come for the final USG
follow-up. Initiating anti-hyperlipidemic therapy was the
protocol violation that led to the exclusion of 5 parti-
cipants from the study. Flowchart of the study is shown
in Figure 1.
Overall, mean baseline characteristics of the 87
enrolled subjects were aged 51 ± 8 years (ranging from 36
to 74 years), BMI 27.2 ± 4.6 kg/m2, TC 5.7 ± 0.6 mmol/L,
93 subjects were excluded
78 no NAFLD
1 for metastatic HCC
4 for other medical 
reasons
10 declined to 
participate
10 subjects assigned to placebo 
did not complete the study
6 withdrew from the study
2 were excluded for 
protocol violation
2 missed final USG
180 hypercholesterolaemic subjects were assessed for eligibility 
87 subjects fulfilled inclusion criteria and were 
randomised
43 subjects were assigned to and received 
tocotrienols
13 subjects assigned to 
tocotrienols did not complete the 
study
8 withdrew from the study
3 were excluded for protocol 
violation
2 missed final USG
30 subjects assigned to tocotrienols 
completed the study and underwent 
baseline & final USG
44 subjects were assigned to and received 
placebo
34 subjects assigned to placebo completed 
the study and underwent baseline & final 
USG
Figure 1 CONSORT Flow-chart of the clinical trial, with reason for exclusion of assessed subjects and for subjects that did not
concluded the study. HCC = Hepatocellular carcinoma; USG = ultrasonography examination.
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Thirty subjects (34.5%) were normoweight (BMI below
25), 37 (42.5%) overweight (BMI ranging between 25 and
30), 19 (21.8%) obese (BMI between 30 and 40) and only 1
(1.1%) subject was morbidly obese (BMI between 40 and
50). Nine subjects (10.3%) had impaired fasting glucose
(IFG) above 7.0 mmol/L. Mild fatty liver was the most
common finding with 69 (79.3%) cases, while moderate
and severe fatty liver were found in 15 (17.2%) and 3
(3.4%) subjects, respectively. Ten participants (11.5%)
were smokers, equally distributed amongst tocotrienols
(11.6%) and placebo groups (11.4%), respectively. The two
groups of enrolled subjects were found to be homoge-
neous with regard to baseline characteristics (Table 2).
Outcomes of USG hepatic evaluation
As for primary objective (Table 3), applying the intention
to treat analysis to all the 87 initially randomised sub-
jects, 43 in the tocotrienols group and 44 in the placebo
group, a statistically significant advantage was seen for
tocotrienols versus placebo for the normalisation of hep-
atic echogenic response (P = 0.039; Odds Ratio [OR] =
2.411; 95% Confidence Interval [CI] = 0.896-6.488; Num-
ber Needed to Treat [NNT] = 6).
The secondary objective per protocol analysis of the
subjects that concluded the study, thus underwent the
final USG examination, showed that 15 out of 30 patients(50.0%) in the tocotrienols group were found with normal
echogenic response compared to only 8 out of 34 patients
(23.5%) of the placebo group. Patients randomised to
tocotrienols after 1 year of treatment presented a sta-
tistically significant normalisation of echogenic response
compared to placebo (P = 0.014; OR = 3.250; 95% CI =
1.117-9.456; NNT = 3.8).
Details of the clinical evaluation of subjects and rela-
tive changes after 1 year of treatment are presented in
Table 4.
Worsening of steatotic grade was seen in two cases in
the placebo group, but none in the tocotrienols group.
Furthermore, amelioration of steatotic grade of more
than one degree has been recorded in one male subject
of the tocotrienols group, that improved from severe to
mild and in two male subjects that improved from mod-
erate to negative. Whereas no changes of more than one
degree were observed in the placebo group.
Blood biochemistry
No statistically significant changes were seen amongst
the two groups of subjects between baseline and conclu-
sion of the study (Table 5) with regard to blood bio-
chemistry results. Exception was ApoB, that showed a
statistically (P = 0.046), but not clinically significant dif-
ference since the values were within the normal range.
This difference was explained with gender difference for






Gender (female) 23 (53.5%) 30 (68.2%) 0.160
Age in years (range) 52 ± 9 (36-74) 49 ± 7 (38-68) 0.177
BMI (kg/m2) 27.2 ± 4.6 27.1 ± 4.6 0.873
Normoweight (BMI < 25) 16 (37.2%) 14 (31.8%)
Overweight (25 < BMI < 30) 16 (37.2%) 21 (47.7%)
Obese (30 < BMI < 40) 11 (25.6%) 8 (18.2%)
Morbidly Obese (40 < BMI < 50) 0 (0.0%) 1 (2.3%)
TC (mmol/L) 5.9 ± 0.6 5.6 ± 0.6 0.075
HDL (mmol/L) 1.44 ± 0.35 1.37 ± 0.30 0.611
LDL (mmol/L) 3.7 ± 0.6 3.6 ± 0.6 0.168
TG (mmol/L) 1.5 ± 0.7 1.6 ± 0.8 0.889
ALP (IU/L) 76 ± 21 72 ± 18 0.826
AST (IU/L) 36 ± 14 38 ± 13 0.381
ALT (IU/L) 35 ± 16 39 ± 22 0.611
GGT (IU/L) 33 ± 19 32 ± 19 0.712
hs-Crp (mg/L) 4.3 ± 7.1 4.0 ± 5.4 0.865
Apo B (g/L) 1.25 ± 0.20 1.25 ± 0.21 0.952
Lp(A) (mg/dL) 17 ± 14 16 ± 16 0.449
Serum creatinine (μmol/L) 86 ± 13 78 ± 11 0.008
Fasting glucose (mmol/L) 5.4 ± 0.8 6.1 ± 2.3 0.557
IFG≥ 7.0 mmol/L 2 (4.7%) 7 (15.9%)
Systolic (mmHg) 134 ± 18 131 ± 15 0.524
Diastolic (mmHg) 80 ± 9 80 ± 9 0.976
Tobacco, current users 5 (11.6%) 5 (11.4%)
Mild NAFLD (score 3) 34 (79.1%) 35 (79.5%)
Moderate NAFLD (score 4) 7 (16.3%) 8 (18.2%)
Severe NAFLD (score 5-6) 2 (4.7%) 1 (2.3%)
Baseline biochemical, anthropometric and clinical parameters of all patients
enrolled in the study (n = 87). Data are expressed as mean value ± SD; P < 0.05
is considered significant.
Table 2 Abbreviations: BMI Body Mass Index, TC Total Cholesterol,
HDL High Density Lipoprotein, LDL Low Density Lipoprotein,
TG Triglycerides, ALP Alkaline Phosphatase, AST aspartate transaminase,
ALT alanine transaminase, GGT gamma-glutamyl transpeptidase, hs-CRP
high-sensitivity C-reactive protein, ApoB apolipoprotein B, LP(A) lipoprotein A,
IFG Impaired Fasting Glucose, NAFLD Nonalcoholic Fatty Liver Disease.
[Wilcoxon rank test; Numbers’ 09, GraphPad].
Conversion factor mmol/L to mg/dL for optimal normal values:
TC 5.2 mmol/L = 200 mg/dL;
HDL 1.55 mmol/L = 60 mg/dL;
LDL 2.6 mmol/L = 100 mg/dL;
TG 1.7 mmol/L = 151 mg/dL.
Table 3 Intention to treat analysis of enrolled study
subjects
Completion of the study
Baseline (n = 87) Normal echogenic response Fatty liver
Tocotrienols (n = 43) 15/43 28/43
34.9% 65.1%
Placebo (n = 44) 8/44 36/44
18.2% 81.8%
Tocotrienols vs Placebo P = 0.038
Drop-out subjects were computed as having an unchanged diagnosis of fatty
liver from baseline.
[Helmert-Pearson’s Chi Square; Numbers’09, GraphPad].
Table 4 Per protocol analysis of ultrasound examination
Tocotrienols
group (n = 30)
Changes at completion
of the study
Baseline Negative Mild Moderate Severe
Mild (n = 22) 13/22 9/22 0/22 0/22
73.3% 59.1% 40.9% 0.0% 0.0%
Moderate (n = 6) 2/6 4/6 0/6 0/6
20.0% 33.3% 66.7% 0.0% 0.0%
Severe (n = 2) 0/2 1/2 0/2 1/2
6.7% 0.0% 50.0% 0.0% 50.0%
TOTAL 15/30 14/30 0/30 1/30





Baseline Negative Mild Moderate Severe
Mild (n = 27) 8/27 17/27 2/27 0/27
79.4% 29.6% 63.0 7.4% 0.0%
Moderate (n = 6) 0/6 5/6 1/6 0/6
17.6% 0.0% 83.3% 16.7% 0.0%
Severe (n = 1) 0/1 0/1 1/1 0/1
2.9% 0.0% 0.0% 100.0% 0.0%
TOTAL 8/34 22/34 4/34 0/34
23.5% 64.7% 11.8% 0.0%
Tocotrienols
vs Placebo
Chi Sq = 4.851 P = 0.014
Details of the clinical evaluation of subjects at baseline and relative changes
after 1 year of treatment.
[Helmert-Pearson’s Chi Square; Numbers’09, GraphPad].
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for male and female respectively. Overall, blood
biochemistry results indicated that tocotrienols did not
significantly affect lipid profile and liver function when
compared with placebo. However, a statistically sig-
nificant reduction of total cholesterol (P = 0.008), LDL
(P = 0.041) and TG (P = 0.027) in the tocotrienols groupcompared to baseline was observed. Within the placebo
group TG values were significantly decreased compared
to baseline in similar magnitude as the treatment group
(P = 0.027). On the other hand, reduction of total cho-
lesterol (P = 0.210) and LDL (P = 0.106) compared to
baseline were not significant.
Plasma levels of alpha-tocopherol were in the nor-
mal reported range of 5.5-18.0 μg/ml [15] for all pa-
tients. The mean baseline levels of alpha-tocopherol
were similar for the two groups of participants, being







BMI (kg/m2) -0.6 -0.3 0.527
TC (mmol/L) -0.3 -0.2 0.055
HDL (mmol/L) -0.04 0.02 0.778
LDL (mmol/L) -0.2 -0.1 0.052
TG (mmol/L) -0.2 -0.2 0.814
ALP (IU/L) -7.0 1.4 0.471
AST (IU/L) -4.8 -3.4 0.207
ALT (IU/L) -5.9 -0.6 0.118
GGT (IU/L) -1.4 -4.2 0.364
C-rp (mg/L) -0.2 -0.2 0.835
Apo B (g/L) -0.01 -0.03 0.046







Systolic (mmHg) 0.1 0.6 0.660
Diastolic (mmHg) -0.3 -2.4 0.607
Mean changes in anthropometric and laboratory parameters for the study
subjects after 1 year of treatment. P < 0.05 is considered significant.
[ANOVA for split-plot design adjusted for unweighted means; Numbers’09].
Abbreviations as in Table 2.
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tocotrienols groups, respectively. At conclusion of the
study, the values for alpha-tocopherol were substantially
unchanged in the placebo group with a mean concen-
tration of 13.4 ± 7.0 μg/ml. Whereas, in the tocotrienol
group the values of alpha-tocopherol were found to be
18.5 ± 6.8 μg/ml. Nevertheless, the changes in alpha-
tocopherol levels were found to be statistically non-
significant (P = 0.665).
Baseline tocotrienol levels were negligible in both
groups. Only alpha-tocotrienol was above the mini-
mum limit of quantification, with 25.0 ± 21.0 ng/ml
and 26.7 ± 32.6 ng/ml for tocotrienols and placebo
group respectively. Gamma- and delta-tocotrienols
were below the minimum limit of quantification in
both groups.
High levels of tocotrienols were measured in all
participating volunteers of the tocotrienols group at
conclusion of the study, thus confirming a good level of
compliance. Mean values were 212.0 ± 379.3 ng/ml,
181.4 ± 440.8 ng/ml and 41.4 ± 98.4 ng/ml for alpha-,
gamma- and delta-tocotrienol respectively. On the other
hand, they were negligible in the placebo group, with
21.7 ± 27.9 ng/ml for alpha-tocotrienol and below the
minimum limit of quantification for gamma- and delta-
tocotrienols.Discussion
Vitamin E, as alpha-tocopherol has been widely investi-
gated in liver diseases earning the status of most promis-
ing treatment at a daily dosage of 533.3 mg (or 800 IU)
in non-diabetics with biopsy-proven NASH [16]. The
present study is the first to consider the hepatoprotec-
tive effects of tocotrienols. Their effectiveness in amelior-
ating NAFLD could in part be explained by the fact that
the tocotrienols have been shown to distribute preferen-
tially to the liver [6,7] where alpha-tocotrienol has been
found to exert a 40-60 times more potent antioxidant
activity in microsomal lipid peroxidation [8]. Oxidative
stress has been recognised amongst the contributing fac-
tors in the progression of steatosis [2,17] with involvement
of nuclear factor-κΒ (NF-κΒ) activation and increased
release of proinflammatory cytokines, such as tumour
necrosis factor alpha (TNFα) and the interleukin-6 (IL-6)
representing the second insult in the “two hits” model
[18,19]. Tocotrienols were reported to inhibit TNFα and
to “prevent reactive oxygen species-induced NF-κΒ ex-
pression” to a higher extent compared to alpha-tocopherol
in streptozotocin-treated diabetic rats [20]. Recently, bio-
logical mechanisms for the activity of tocotrienols against
hepatic triglycerides accumulation have been reported. It
has been shown that gamma-tocotrienol, but not alpha-
tocopherol, was able to attenuate triglycerides accu-
mulation by regulating fatty acid syntase and carnitine
palmitoyltransferase leading to a reduction of hepatic in-
flammation and endoplasmic reticulum stress [21,22]. A
16-week study on rats fed high fat and high carbohydrate
diet, showed a reduction of the hepatic fatty changes with
“normalised portal inflammatory cells” [23]. The authors
suggested that interference with the inflammatory pro-
cesses to be one of the possible mechanisms for hepato-
protection [23].
Clinical trials employing the same mixed tocotrienols
preparation used in the present study has been shown to
be effective in improving arterial compliance [24] and in
reducing Model for End-stage Liver Disease (MELD)
score [7]. Moreover, the lipid lowering activity of toco-
trienols has been previously reported [25] and a modest
reduction of lipid profile was recorded also in the
present study. Blood lipids biochemistry results showed
that tocotrienols significantly reduced TC, LDL and TG
compared to baseline, but not compared to placebo.
However, the values for TC and LDL were still above the
normality range.
In our study, baseline levels of alpha-tocopherol did
not differ between the two groups. The plasma alpha-
tocopherol concentrations of subjects in the tocotrienols
treated group at conclusion of the study were found to
be slightly higher than baseline, although not statistically
significant. The presence of 61.1 mg of alpha-tocopherol
in the mixed tocotrienols preparation administered may
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tocopherol. Nevertheless, mean plasma concentrations
of alpha-tocopherol in the participating subjects were
still within the normal range of 5.5-18.0 μg/ml reported
by the National Reference Laboratory [15] throughout
the study, irrespective of the treatment received. The
presence of alpha-tocopherol in the mixed tocotrienols
capsules was unlikely to have any influence on the out-
comes of the present study since the amount present in
the capsules was far below those used in earlier studies
with negative outcomes [26-29].
We acknowledge that histology examination is the
gold standard for evaluation of liver diseases and the use
of USG might represent an intrinsic limitation. However,
USG examination has been shown to have adequate
sensitivity and specificity, in particular as front line
evaluation of non-advanced fatty liver.
Diagnostic reports showed that USG has specificity
range of 60-100% and sensitivity range of 80-100%
[30-32]. Obesity with BMI above 40 might affect USG
evaluation, reducing specificity and sensitivity when fat
infiltration is below 33% [33]. In the present study, only
one morbid obese was enrolled whose baseline diagnosis
of NAFLD was unchanged at conclusion.
A gross advantage of USG is that the liver is seen in
full, while a needle biopsy only samples about one
50,000th of the organ and area sampling error could be
an issue in non-advanced cases [31,34]. The choice of
investigating hepatoprotective activity of a nutritional
supplement, such as mixed tocotrienols, in adults drawn
from a population-based study [10] with the use of non-
invasive USG has to be seen in this light, being the
majority of patients classified as mild steatosis with
normal to slightly elevated liver aminotransferases, thus
a non-advanced stage of NAFLD.
A possible weakness of our study may lie in the use
of USG versus other non-ionising imaging methodolo-
gies such as proton magnetic resonance spectroscopy
(1H MRS). 1H MRS is a powerful and objective tool
for assessing fat fraction in the liver, even though it lacks
of “information about regional fat distribution” [35].
A recent study [36] aimed at correlating 1H MRS with
the echodiscrepancy ratio between kidney and liver as
indicator of steatosis, on subjects with essentially similar
anthropometric and blood biochemical values to our
present study, concluded that the hepatorenal echodiscre-
pancy ratio evaluated with USG is in accord with the
quantitative data obtained from 1H MRS for hepatic lipid
infiltration in the range 1%-30% for comparable severity of
steatosis, albeit what Mancini [36] considered as moderate
in their study, is categorised as mild in ours.
We acknowledge that our patients were a low-risk
cohort. However, patients with similar characteristics as
those considered in our study, including normal livertransaminases levels, have been shown to still be at risk
with respect to progression of NAFLD [37,38].
In view of the not fully elucidated reasons for steatosis
to progress to more advanced stages of liver disease, it
might be beneficial to manage the condition during the
early stages, such as at the steatotic stage. Hence, in view
of our findings, mixed tocotrienols might be considered
for the treatment of steatosis.
In summary, the present study showed that patients
assigned to tocotrienols at the current dosage, have
significantly benefited in terms of normalisation of the
hepatic echogenic response in NAFLD compared to
placebo during the 1-year treatment. We acknowledge
that this is a pilot study and therefore larger cohort
studies should be warranted to further confirm the posi-
tive results of tocotrienols in NAFLD of the present
study. Furthermore, at the current combined dosage of
400 mg/d used in the present study, the mixed tocotrie-
nols were well tolerated and no adverse reactions were
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